Company Profile

BlueWillow Biologics Inc (AKA: NanoBio Corporation)
Profile last edited on: 8/18/2020      CAGE: 3HT71      UEI: RL3UZ5ZDKFT8

Business Identifier: Intranasal and intramuscular vaccines, based on patented NanoStatTM vaccine adjuvant platform
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2311 Green Road Suite A
Ann Arbor, MI 48107
   (734) 302-4000
Location: Single
Congr. District: 06
County: Washtenaw

Public Profile

A spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and initially focused on developing nano-scale dermatology applications. Applicant for SBIR-STTR Support under the name of Nanobio Corporation, soon after.the name of the company was changed to BlueWillow Biologics better to reflects evolution towards the focus on vaccines and advancing the firm's novel intranasal technology to develop new vaccines for several respiratory and sexually transmitted diseases. BlueWillow Biologics® is a privately-held biopharmaceutical company organized around developing and commercializing vaccines using its patented NanoVax® technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination, and can elicit both mucosal and systemic immunity when applied intranasally. BlueWillow is currently developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  David Peralta -- CEO

  James R Baker -- Founder, Chairman & Chief Science Officer

  Fiona Cameron -- Regulatory Consultant

  Susan Ciotti -- Director of Formulations

  John Coffey -- Foounder, Vice President of Business Development

  Ali I Fattom -- Sr. Vice President Vaccine Research and Development

  Stephen (Steve) Gracon -- Regulatory Consultant

  Tarek Hamouda -- Senior Director of Clinical Research

  Frances Kivel -- Clinical Operations Consultant

  Keith Lerner

  Lyou-fu Ma -- Sr. V.P of Development

  Frank J Malinoski -- Clinical Consultant

  David D Muth -- Global Head of Business Development

  Laura Scallion

  Douglas M Smith -- Director of Immunology